

# Upal Roy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2550395/publications.pdf>

Version: 2024-02-01

32  
papers

1,130  
citations

471509  
17  
h-index

454955  
30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1680  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimicrobial activity of marine bacteria associated with sponges from the waters off the coast of South East India. Microbiological Research, 2006, 161, 252-262.	5.3	131
2	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	2.2	121
3	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release, 2011, 150, 204-211.	9.9	107
4	Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Scientific Reports, 2016, 6, 25309.	3.3	92
5	Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain. Scientific Reports, 2018, 8, 1603.	3.3	72
6	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2013, 57, 3110-3120.	3.2	70
7	MRP (ABCC) Transporters-Mediated Efflux of Anti-HIV Drugs, Saquinavir and Zidovudine, from Human Endothelial Cells. Experimental Biology and Medicine, 2008, 233, 1149-1160.	2.4	68
8	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1-Infected Human Peripheral Blood Lymphocyte- Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	4.0	62
9	Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. International Journal of Nanomedicine, 2012, 7, 2373.	6.7	48
10	The potential of HIV-1 nanotherapeutics: from <i>in vitro</i> studies to clinical trials. Nanomedicine, 2015, 10, 3597-3609.	3.3	43
11	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. International Journal of Nanomedicine, 2011, 6, 3393.	6.7	37
12	UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2332-2338.	2.3	33
13	Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells. Biopolymers, 2013, 100, 471-479.	2.4	26
14	Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue. International Journal of Nanomedicine, 2015, 10, 5819.	6.7	25
15	Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection. Retrovirology, 2011, 8, 3.	2.0	23
16	Montelukast Is a Potent and Durable Inhibitor of Multidrug Resistance Protein 2-Mediated Efflux of Taxol and Saquinavir. Biological and Pharmaceutical Bulletin, 2009, 32, 2002-2009.	1.4	19
17	Immunoneuropathogenesis of HIV-1 clades B and C: Role of redox expression and thiol modification. Free Radical Biology and Medicine, 2014, 69, 136-144.	2.9	19
18	The Membrane-Active Phytopeptide Cycloviolacin O2 Simultaneously Targets HIV-1-infected Cells and Infectious Viral Particles to Potentiate the Efficacy of Antiretroviral Drugs. Medicines (Basel,) Tj ETQq0 0 0 rgBT /Overclock 10 16 50 57 Td		

#	ARTICLE	IF	CITATIONS
19	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visualized Experiments, 2010, , .	0.3	17
20	Specific Increase in MDR1 Mediated Drug-Efflux in Human Brain Endothelial Cells following Co-Exposure to HIV-1 and Saquinavir. PLoS ONE, 2013, 8, e75374.	2.5	17
21	Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections. Frontiers in Microbiology, 2015, 6, 948.	3.5	15
22	Microbial transformation of tributyltin chloride by Pseudomonas aeruginosa strain USS25 NCIM-5224. Applied Organometallic Chemistry, 2006, 20, 5-11.	3.5	14
23	Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology, 2007, 16, 253-261.	2.4	14
24	Molecular and phylogenetic analysis of a novel family of fibrinogen-related proteins from mosquito Aedes albopictus cell line. Computational Biology and Chemistry, 2008, 32, 382-386.	2.3	9
25	Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load. Scientific Reports, 2019, 9, 5963.	3.3	8
26	Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro. Journal of Medical Virology, 2008, 80, 494-500.	5.0	7
27	DJ1 expression downregulates in neuroblastoma cells (SK-N-MC) chronically exposed to HIV-1 and cocaine. Frontiers in Microbiology, 2015, 6, 749.	3.5	6
28	Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection. Nanomedicine, 2022, 17, 959-978.	3.3	5
29	The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley. Current HIV Research, 2020, 17, 377-387.	0.5	2
30	Partial genomic organization of ribosomal protein S7 gene from malaria vector Anopheles stephensi. Insect Science, 2007, 14, 101-106.	3.0	1
31	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Research and Human Retroviruses, 2021, 37, 807-820.	1.1	1
32	HIV Infection and Adipose Tissue Resident Stem Cells: Their Involvement in Pathology and Treatment. Stem Cells and Cancer Stem Cells, 2015, , 21-34.	0.1	0